Chinese Journal of Integrative Medicine

, Volume 24, Issue 3, pp 185–192 | Cite as

Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction (桃红四物汤) for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial

  • Jing Zhou
  • Dong Yang
  • Shu-hong Zhou
  • Jin-ping Wang
  • Yue-shu Liu
  • Shu-lan Wang
Original Article



To examine the efficacy and safety of bathing therapy with Taohong Siwu Decoction (桃红四物汤, TSD) in the treatment of early-stage, mild-moderate diffuse cutaneous systemic sclerosis (dcSSc).


This randomized, placebo-controlled trial enrolled 148 men and women (18–60 years) with dcSSc (disease duration 12 months) and baseline modified Rodnan skin score (MRSS) 10. Patients were randomized into a TSD group (71 cases bathing with TSD plus oral prednisone) or control group (71 cases bathing with placebo plus oral prednisone). Bathing (40 °C, 30 min) of the upper and lower limbs was carried out once daily for 12 consecutive weeks. The primary outcome measure was MRSS; secondary outcomes were Raynaud’s phenomenon (RP) score, quality of life (QOL), physician visual analogue scale (VAS), patient VAS, percent predicted diffusing capacity for carbon monoxide (DLCO), percent predicted forced vital capacity (FVC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level and overall treatment effect.


The final analysis included 135 patients (control group, 68 cases; TSD group, 67 cases). Primary and secondary outcome measures after 2 weeks of treatment showed no improvement (versus baseline) in both groups, with no differences between groups. At 12 weeks, QOL, physician VAS, patient VAS, ESR and CRP were improved in both groups, but MRSS and RP score were improved only in the TSD group (all P<0.05). MRSS, RP score, QOL, physician VAS, patient VAS, ESR and CRP differed significantly between groups (all P<0.05). Meanwhile, the overall treatment effect was significantly higher in the TSD group than in the control group (P<0.05). Adverse events in the two groups were similar (P>0.05).


Bathing with TSD plus oral prednisone achieves better outcomes than oral prednisone alone in patients with dcSSc and is not associated with serious adverse events.


Chinese medicine bathing therapy systemic sclerosis treatment efficacy adverse effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol 2015;6:272.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sticherling M. Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges 2012;10:705–718.PubMedGoogle Scholar
  3. 3.
    Wielosz E, Dryglewska M, Majdan M. Serological profile of patients with systemic sclerosis. Postepy Hig Med Dosw (Online) 2014;68:987–991.CrossRefGoogle Scholar
  4. 4.
    Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol 2013;32:617–621.CrossRefPubMedGoogle Scholar
  5. 5.
    Chung L, Denton CP, Distler O, Furst DE, Khanna D, Merkel PA. Clinical trial design in scleroderma: where are we and where do we go next? Clin Exp Rheumatol 2012;30:S97–S102.PubMedGoogle Scholar
  6. 6.
    Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194–1203.CrossRefPubMedGoogle Scholar
  7. 7.
    Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351–1358.CrossRefPubMedGoogle Scholar
  8. 8.
    Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, et al. Imatinib mesylate in sclerodermaassociated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012;167:1138–1144.CrossRefPubMedGoogle Scholar
  9. 9.
    Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2009;60:1102–1111.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573–1576.PubMedGoogle Scholar
  11. 11.
    Zhao D, Wang F. The study progress of TCM on systemic sclerosis. J Hubei Univ Nat (Chin) 2014;31:936–938.Google Scholar
  12. 12.
    Wang WL, Su YM, Yang RY, Zhang J, Xu Y. Followup efficacy of integrative Chinese and Western drugs on localized scleroderma with vitamine B6 and Xuefu Zhuyu Decoction. Chin J Integr Med 2005;11:34–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Yan XN, Han SR, Li WB, Li MH, Liu YT. Effects of Refu Yao on mice models with scleroderma of COL-I and COL-III. Chin J Dermatovenerol Integr Tradit West Med (Chin) 2011;10:353–355.Google Scholar
  14. 14.
    Wu L. Literature analysis of external treatment of traditional Chinese medicine (TCM) on scleroderma and exploration of drug laws. J Chengdu Univ Tradit Chin Med (Chin) 2014:12–36.Google Scholar
  15. 15.
    Geyer M, Muller-Ladner U. The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 2011;40:92–103.CrossRefPubMedGoogle Scholar
  16. 16.
    van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–2747.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang H, Liu T, Li F. A random, case-control study on the efficacy and safety of Weishi Bitong Xifang Fumigation for mild and moderate knee osteoarthritis patients. Int J Rheum Dis 2015;18:502–507.CrossRefPubMedGoogle Scholar
  18. 18.
    Foocharoen C, Thinkhamrop B, Mahakkanukrauh A, Suwannaroj S, Netwijitpan S, Sripavatakul K, et al. Interand intra-observer reliability of modified Rodnan Skin Score assessment in thai systemic sclerosis patients: a validation for multicenter scleroderma cohort study. J Med Assoc Thai 2015;98:1082–1088.PubMedGoogle Scholar
  19. 19.
    Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, et al. Iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology (Oxford) 2006;45:999–1004.CrossRefGoogle Scholar
  20. 20.
    Georges C, Chassany O, Mouthon L, Tiev K, Marjanovic Z, Meyer O, et al. Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis. Rev Med Intern 2004;25:16–21.CrossRefGoogle Scholar
  21. 21.
    Iudici M, Cuomo G, Vettori S, Avellino M, Valentini G. Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. Health Qual Life Outcomes 2013;11:23.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M. Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 2009;61:1112–1120.CrossRefPubMedGoogle Scholar
  23. 23.
    Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832–840.PubMedGoogle Scholar
  24. 24.
    Zheng XY, ed. Guiding principle of clinical research on new drugs of traditional Chinese medicine. Beijing: Chinese Medicine and Technology Publishing House; 2002.Google Scholar
  25. 25.
    Khanna D, Clements PJ, Postlethwaite AE, Furst DE. Does incorporation of aids and devices make a difference in the score of the health assessment questionnairedisability index? Analysis from a scleroderma clinical trial. J Rheumatol 2008;35:466–468.PubMedGoogle Scholar
  26. 26.
    Wan L, Liu J, Huang CB, Wang Y, Chen X, Zhang WD, et al. Xinfeng Capsule for the treatment of rheumatoid arthritis patients with decreased pulmonary function—a randomized controlled clinical trial. Chin J Integr Med 2016;22:168–176.CrossRefPubMedGoogle Scholar
  27. 27.
    Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 2012;64:1405–1414.CrossRefGoogle Scholar
  28. 28.
    Yang H, Lyu J, Huang LP, Yan YL, He XP. Effects of safflower decoction on the expression of skin vascular endothelial growth factor in mouse with scleroderma. Rheumat Arthritis (Chin) 2014;3:26–30.Google Scholar
  29. 29.
    Han L, Bian H, Ouyang J, Bi Y, Yang L, Ye S. Wenyang Huazhuo Tongluo Formula, a Chinese herbal decoction, improves skin fibrosis by promoting apoptosis and inhibiting proliferation through down-regulation of survivin and cyclin D1 in systemic sclerosis. BMC Complement Altern Med 2016;16:69.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Wu T, Chu H, Tu W, Song M, Chen D, Yuan J, et al. Dissection of the mechanism of traditional Chinese medical prescription—Yiqihuoxue formula as an effective antifibrotic treatment for systemic sclerosis. BMC Complement Altern Med 2014;14:224.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2017

Authors and Affiliations

  • Jing Zhou
    • 1
  • Dong Yang
    • 1
  • Shu-hong Zhou
    • 1
  • Jin-ping Wang
    • 1
  • Yue-shu Liu
    • 2
  • Shu-lan Wang
    • 1
  1. 1.Department of Immunology and RheumatologyGansu Provincial HospitalLanzhouChina
  2. 2.Department of Traditional Chinese MedicineGansu Provincial HospitalLanzhouChina

Personalised recommendations